Roche presents real-world Vabysmo data from 5,000 patients

Roche subsidiary Genentech announced new real-world data from its VOYAGER study evaluating Vabysmo across three major eye conditions. The findings cover wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. Genentech presented the findings at the EURETINA 2026 Annual Meeting in Vienna, Austria.

The VOYAGER registry is a prospective, non-interventional study tracking more than 5,000 patients across 28 countries and regions on six continents. The company reported that vision gains and anatomical improvements matched outcomes previously seen in Phase III clinical trials. Results confirmed reduced subretinal and intraretinal fluid in both previously untreated and treated eyes, with no new safety signals detected.

In the wet AMD and DME cohorts, patients experienced improvements in vision and central subfield thickness over 12 months. Those groups also received fewer Vabysmo injections during months 7 to 12 compared with months 1 to 6, suggesting that treatment intervals could be lengthened. In retinal vein occlusion cohorts, patients showed efficacy improvements after six months of treatment across both branch RVO and central or hemi-RVO subtypes.

Vabysmo is approved in more than 100 countries, including the United States, Japan, the United Kingdom, and the European Union, for wet AMD and DME. It is also cleared in more than 60 countries for macular edema following retinal vein occlusion.